



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_49_26

You asked:

Q1. How many patients has your Trust treated in the past 12 months (January - December 2025) for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Trust do you refer patients needing treatment to?

43.

Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated by the Trust in the past 6 months on the following treatments:

- BR (bendamustine + rituximab) = 0
- Brukinsa (zanubrutinib) = **
- Calquence (acalabrutinib) = 24
- Calquence (acalabrutinib) + Gazyvaro (obinutuzumab) = 0
- Calquence (acalabrutinib) + Venclyxto (venetoclax) = 0
- Calquence (acalabrutinib) + Venclyxto (venetoclax) + Gazyvaro (obinutuzumab) = 0
- FCR (fludarabine + cyclophosphamide + rituximab) = 0
- Fludarabine Monotherapy = 0
- Gazyvaro (obinutuzumab) + chlorambucil = 0
- Imbruvica (ibrutinib) = 5
- Venclyxto (venetoclax) = **
- Venclyxto (venetoclax) + Gazyvaro (obinutuzumab) = **
- Venclyxto (venetoclax) + rituximab = 0
- Zydelig (idelalisib) + rituximab = 0
- Imbruvica (Ibrutinib) + Venclyxto (venetoclax) = **
- Any other systemic anti-cancer therapy = 0

Q3. How many Chronic Lymphocytic Leukaemia (CLL) patients have received treatment for relapsed/refractory CLL in the past 6 months with the following:

- Brukinsa (zanubrutinib) = **
- Calquence (acalabrutinib) = 7
- Imbruvica (ibrutinib) = **
- Venclyxto (venetoclax) = 0
- Zydelig (idelalisib) + rituximab = 0
- Any other systemic anti-cancer therapy = 0

Q4. If your Trust does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If yes, please can you provide details of the ongoing trials.

No.

Please note - Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.